Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC32781 structure
    GC32781CUDC-427 (GDC-0917)
    CAS: 1446182-94-0
    纯度: >98.00%

    CUDC-427 (GDC-0917) 是一种有效的第二代泛选择性 IAP 拮抗剂,用于治疗各种癌症。

  • GC32803 structure
    GC32803ASTX660
    CAS: 1799328-86-1
    纯度: >98.00%

    A non-peptidomimetic inhibitor of IAP protein-peptide interactions

  • GC32807 structure
    GC32807HJC0152 hydrochloride
    CAS: 1420290-99-8
    纯度: >98.50%

    An orally bioavailable inhibitor of STAT3

  • GC32841 structure
    GC32841Catechin ((+)-Catechin)
    CAS: 154-23-4
    纯度: >99.00%

    (+)-Catechin (Cianidanol, Catechinic acid, Catechuic acid) is an antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.

  • GC32853 structure
    GC32853PD0166285
    CAS: 185039-89-8
    纯度: >99.00%

    PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.

  • GC32860 structure
    GC32860RIP2 kinase inhibitor 2
    CAS: 1581270-11-2
    纯度: >99.50%

    RIP2kinaseinhibitor2是一种受体相互作用蛋白-2(RIP2)激酶抑制剂,详细信息请参考专利WO/2014043437A1中的化合物example9。

  • GC32881 structure
    GC32881Milademetan (DS-3032)
    CAS: 1398568-47-2
    纯度: >98.00%

    Milademetan (DS-3032) (DS-3032) 是一种特异性的、具有口服活性的 MDM2 抑制剂,用于研究急性髓性白血病 (AML) 或实体瘤。 Milademetan (DS-3032) (DS-3032) 诱导 G1 细胞周期停滞、衰老和凋亡。

  • GC32895 structure
    GC32895Maytansinol (Ansamitocin P-0)
    CAS: 57103-68-1
    纯度: >99.00%

    An ansa macrolide

  • GC32901 structure
    GC32901ROC-325
    CAS: 1859141-26-6
    纯度: >99.50%

    An autophagy inhibitor

  • GC32911 structure
    GC32911CTX1
    CAS: 501935-96-2

    CTX1是一种新型小分子p53激活剂。

  • GC32919 structure
  • GC32929 structure
    GC32929MIR96-IN-1
    CAS: 1311982-88-3
    纯度: >98.00%

    MIR96-IN-1选择性抑制微小RNA-96的生物合成,上调蛋白靶点(FOXO1)且诱导癌细胞凋亡。

  • GC32946 structure
    GC32946PK11007
    CAS: 38275-34-2
    纯度: >99.00%

    PK11000 stabilizes the DBD of both WT and mutant p53 proteins by covalent cysteine modification without compromising DNA binding and effective in inducing cell death.

  • GC32947 structure
    GC32947S55746 (BLC201)
    CAS: 1448584-12-0
    纯度: >99.50% / >98.00%

    S55746 (S 055746,BCL201) is a novel, orally active BCL-2 specific inhibitor (Ki = 1.3 nM) with poor affinity for BCL-XL and no significant binding to MCL-1, BFL-1 (BCL2A1/A1). The selectivity of S55746 for BCL-2 versus BCL-XL ranges from ~70 to 400 folds.

  • GC32973 structure
    GC32973SID 3712249 (MiR-544 Inhibitor 1)
    CAS: 522606-67-3
    纯度: >99.00%

    An inhibitor of miR-544 biogenesis

  • GC32981 structure
    GC32981A-385358
    CAS: 406228-55-5
    纯度: >98.50%

    A-385358是Bcl-XL的一个选择性抑制剂,对于Bcl-XL和Bcl-2的Ki值分别为0.80和67nM。

  • GC32997 structure
    GC32997Cinchonine ((8R,9S)-Cinchonine)
    CAS: 118-10-5
    纯度: >98.00%

    Cinchonine (LA40221) is an alkaloid and a stereoisomer and pseudo-enantiomer of cinchonidine.

  • GC32998 structure
    GC32998Ginsenoside Rh4
    CAS: 174721-08-5
    纯度: >98.00%

    Ginsenoside Rh4 is an important active ingredient of traditional Chinese medicine ginseng, which has been shown to inhibit Wnt/β-Catenin, JAK2/STAT3, TGF-β/Smad2/3 and other signaling pathways.

  • GC33002 structure
    GC33002PBOX 6
    CAS: 290814-68-5
    纯度: >99.50%

    PBOX6是一种pyrrolo-1,5-benzoxazepine(PBOX)化合物,可作为微管解聚剂和促凋亡剂起作用。

  • GC33029 structure
    GC33029Forodesine (BCX-1777 freebase)
    CAS: 209799-67-7
    纯度: >98.00%

    A nucleoside analog and PNP inhibitor

  • GC33035 structure
    GC33035Mcl1-IN-2
    CAS: 292057-76-2
    纯度: >98.00%

    Mcl1-IN-2 是骨髓细胞因子 1 (Mcl-1) 的抑制剂。 Mcl1-IN-2 是一种非竞争性的德里 metallo-β-lactamase (NDM-1) 抑制剂。

  • GC33043 structure
    GC33043EL-102
    CAS: 1233948-61-2
    纯度: >99.50%

    EL102是HIF1α的抑制剂,能够抑制微管蛋白聚合和减少它的稳定性。

  • GC33052 structure
    GC33052VU0661013
    CAS: 2131184-57-9
    纯度: >98.50%

    VU661013 is a novel, potent, selective MCL1 inhibitor with Ki of 97 ± 30 pM of human MCL-1 in a TR-FRET assay. However, VU661013 does not significantly inhibit BCL-xL or BCL-2 with Ki > 40 μM or = 0.73 μM. VU661013 de-stabilizes BIM/MCL-1 association, leads to apoptosis in AML.

  • GC33074 structure
    GC33074SSE15206
    CAS: 1370046-40-4
    纯度: >98.00%

    SSE15206是一种微管(microtubule)聚合抑制剂,其在HCT116细胞SRB增殖实验中的GI50值为197nM。